Neurology

Relevance of assessing body weight in MS patients

 

A number of studies have indicated that adolescent obesity is a risk factor for the development of MS, most notably in patients with the HLA-DRB1*15 genotype (Hedstrom et al. Mult Scler 2015; epublished September 11, 2015; Hedstrom et al. Neurology 2014;82:865-872). The relationship between obesity and clinical course once MS has been diagnosed is less clear. A recent study found that obesity (body-mass index >30 kg/m2) did not appear to be associated with increased severity (relapse rate), or disability (EDSS score), nor was obesity linked to the presence of oligoclonal bands (Coban et al. Obes Res Clin Pract 2015;9:533-535).

A study of older MS patients (mean age 55.8 years) with significant disability (mean EDSS 5.5) found that obese and non-obese subjects were comparable with respect to EDSS score and number of steroid courses received (Pinhas-Hamiel et al. Eur J Neurol 2015;22:1275-1279). Read More

TOPICS:

Social Media Survey – Part 1 now completed!

 

Thank you to all neurologists who completed the social media survey. The data are now being analysed by Dr. Jiwon Oh, University of Toronto, and an abstract of the results will be submitted for presentation at an upcoming international congress.

COMING SOON… Part 2 of the social media survey.

Watch for our announcement in an upcoming issue of NeuroSens.

Pioglitazone not effective in PD

 

Pioglitazone is a PPAR (peroxisome proliferator-activated receptor)-gamma agonist of the thiazolidinedione class that is used to treat insulin resistance in patients with Type 2 diabetes. Prior studies in the MPTP mouse model reported that the drug prevented dopaminergic cell loss in the substantia nigra (Breidert et al. J Neurochem 2002;82:615-624). The implication was that the drug might be usefully employed as a neuroprotective agent in Parkinson’s disease. Read More

TOPICS: